Technology
Health
Biotechnology

Bio-Path Holdings

$14.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-0.82%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BPTH and other stocks, options, ETFs, and crypto commission-free!

About

Bio-Path Holdings, Inc. Common Stock, also called Bio-Path Holdings, is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Read More Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Employees
8
Headquarters
Bellaire, Texas
Founded
2007
Market Cap
9.89M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.06M
High Today
$14.87
Low Today
$14.33
Open Price
$14.71
Volume
25.50K
52 Week High
$73.52
52 Week Low
$1.61

Collections

Technology
Health
Biotechnology
US
North America

News

Seeking AlphaMay 16

Bio-Path Holdings, Inc. CEO Peter Nielsen on Q1 2019 Results - Earnings Call Transcript

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q1 2019 Earnings Conference Call May 16, 2019 8:30 AM ET Company Participants Peter Nielsen - President, Chief Executive Officer Anthony Price - Vice President, Finance and Accounting Will O’Connor - Stern Investor Relations Conference Call Participants Laura Engle - Stonegate Capital Partners Operator Good morning ladies and gentlemen. Welcome to the Bio-Path Holdings full year 2018 earnings conference call. At this time, all participants are in a listen-only m...

603
Yahoo FinanceApr 29

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)

BELLAIRE, TX / ACCESSWIRE / April 29, 2019 / Bio-Path Holdings, Inc. (BPTH). The full report can be accessed by clicking on the following link: http://stonegateinc.com/reports/BPTH%20Update%20April%202019%20Final%20v4.pdf Company Description Bio-Path Holdings, Inc. (Bio-Path) is a clinical stage biotechnology company that focuses on developing nucleic acid cancer therapeutics using its proprietary nanoparticle RNAi antisense technology called DNAbilize®. This technology safely distributes nucleic acid b...

1,088

Earnings

-$0.89
-$0.60
-$0.31
-$0.02
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
-$0.89 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.